Treatment with CS1, a once-daily oral therapy being developed by Cereno Scientific, was found to be safe and well tolerated for people with pulmonary arterial hypertension (PAH), according to one-year data from an expanded access program (EAP). The EAP (NCT06321705), also known as compassionate use in the…
In a large clinical trial, treatment with Winrevair (sotatercept-csrk) significantly reduced pressure in the lungs’ blood vessels among adults with a form of pulmonary hypertension associated with heart failure, according to newly published data. The injection therapy, approved in the U.S. for…
A history of smoking was associated with worse survival outcomes in male patients with pulmonary arterial hypertension (PAH), according to a new study. The analysis found, however, that smoking history did not significantly affect survival in female PAH patients or in people with chronic thromboembolic pulmonary hypertension (CTEPH).
The proportion of people in the U.S. with pulmonary arterial hypertension related to the use of methamphetamine (Meth-PAH) increased by 93% between 2018 and 2022, a steeper increase than the one seen for the number of U.S. adults self-reporting methamphetamine use, a new study shows. The analysis found that Meth-PAH patients…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
